Pharmaust Limited (AU:NUZ) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Neurizon Therapeutics Limited, a biotech firm focused on neurodegenerative disease treatments, has updated its Securities Trading Policy, as announced on the ASX. The company is actively advancing its lead drug candidate, NUZ-001, which targets ALS, the most prevalent form of motor neurone disease. This update aligns with Neurizon’s commitment to accelerating treatment access and exploring broader applications for its drug.
For further insights into AU:NUZ stock, check out TipRanks’ Stock Analysis page.